Single-use technology manufacturing can attain cost-of-goods that are comparable to stainless-steel systems, noted WuXi.

The entire clinical development process may last 6-11 years. WuXi’s phase 1 and phase ... can’t manufacture everything in-house. Biologics manufacturing requires quality certificates and ...

Dr. Chris Chen, CEO of WuXi Biologics, commented ... the company has applied SUT manufacturing in over 300 batches of scaled production ranging from 4,000L to 16,000L across multiple facilities ...

Revenue: For the year ended December 31, 2024, the Group's revenue grew 9.6% YoY to RMB18,675. ... platforms that accelerate biologics development and manufacturing. Key platforms include WuXia ...

WuXi Biologics is committed ... disease project completed in just 6 months. By leveraging single-use technology (SUT), the company scaled manufacturing from 4,000 to 16,000 liters across its ...

SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ... project completed in just 6 months. By leveraging single-use technology (SUT), the company scaled manufacturing from 4,000 to 16,000 ...

HONG KONG, March 25, 2025 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269), a leading global Contract Research, Development and Manufacturing ...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pacific ...